comprehensive -WSS

comprehensive

author：fashion 2025-09-02 11:37:56 - browse：8

Blood samples — Marion Berard/AFP/GettyImages

With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is bracing for the crush.

Based on their ability to slow cognitive decline, the Eisai/Biogen drug Leqembi won full approval from the FDA this month, and donanemab by Eli Lilly could be approved by year end. Clinicians now have to decide which patients are most suitable for treatment, which means better Alzheimer’s tests need to be developed.

“There’s going to be capacity issues because there’s just not enough neurologists in the world to treat this pool of patients with Alzheimer’s disease at the moment,” said Mark Stearman, a senior international product manager at Roche focusing on Alzheimer’s diagnostics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： How the Dana

explore

WSS

Apple Watch's A

Sanofi strikes deal with Novavax, boosting the vaccine maker

Study: AI not yet building 'n

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Would Medicare drug price negotiations stall in a shutdown?

Did you have Obamacare on your GOP debate bingo card?

explore

comprehensive

leisure time

Virginia high school admissions case could be legal follow

H5N1 bird flu: what we're starting to learn about infection in cows

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Use wet bulb globe temperature, not heat index, to protect workers

Guidelines to prevent youth baseball injuries need more muscle

Mindstrong's demise and the future of mental health care

DIEP, the 'gold standard' of breast reconstruction, is under threat

Sanofi strikes deal with Novavax, boosting the vaccine maker

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Biogen shutters digital health group, ends Apple study, in cost cutting move

entertainment

Shingles, which affected Dianne Feinstein, is on the rise

After gene therapy, two congenitally deaf children hear for the first time

Study: AI not yet building 'n

How to improve immunocompromised access to mAb treatments

Researchers on aging grapple with how to calculate biological age

FDA seeks to regulate lab

entertainment

explore

leisure time

explore